<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1496">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141682</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-21018</org_study_id>
    <secondary_id>NCI-2021-08491</secondary_id>
    <nct_id>NCT05141682</nct_id>
  </id_info>
  <brief_title>Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I Dose-Finding Clinical Trial With Expansion Cohort Evaluating CC-486 in Patients With Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Brammer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose, possible benefits and/or side effects of oral&#xD;
      azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has&#xD;
      come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy&#xD;
      drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and maximum tolerated dose (MTD) of oral azacitidine (CC-486) in&#xD;
      patients with symptomatic T-cell large granular lymphocytic leukemia (T-LGLL). (Phase I) II.&#xD;
      To determine the overall response rate (complete response [CR] and partial response [PR]) of&#xD;
      CC-486 in patients with T-LGLL. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Duration of response to CC-486. II. Progression-free survival. III. Rate of conversion&#xD;
      from PR at 4 months to CR at 8 and 12 months. IV. Rate of molecular remission (T-cell&#xD;
      receptor [TCR] clearance, STAT3 mutation clearance) at 4, 8, 12 months.&#xD;
&#xD;
      V. Effect of treatment on IL-15 promoter demethylation. VI. Effect of CC-486 on IL-15&#xD;
      promoter demethylation. VII. Safety of CC-486 in T-LGLL patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive azacitidine orally (PO) on days 1-14. Treatment repeats every 28 days for 4&#xD;
      cycles in the absence of disease progression or unacceptable toxicity. Patients with PR or CR&#xD;
      continue treatment for up to 8 additional cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of oral azacitidine (CC-486) (Phase I)</measure>
    <time_frame>Up to 4 cycles (1 cycle = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (complete response [CR] + partial response [PR]) (Phase II)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Assessed by the investigator based upon criteria derived from the ECOG 5998 and BNZ-1 clinical trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response to CC-486</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion from PR at 4 months to CR at 8 months</measure>
    <time_frame>From 4 months to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion from PR at 4 months to CR at 12 months</measure>
    <time_frame>From 4 months to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular remission (T-cell receptor [TCR] clearance, STAT3 mutation clearance)</measure>
    <time_frame>At 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular remission (TCR clearance, STAT3 mutation clearance)</measure>
    <time_frame>At 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular remission (TCR clearance, STAT3 mutation clearance)</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment-emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of IL-15 promoter demethylation in responders versus non-responders</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Recurrent T-Cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Refractory T-Cell Large Granular Lymphocyte Leukemia</condition>
  <condition>T-Cell Large Granular Lymphocyte Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (Oral Azacitidne)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Azacitidine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (Oral Azacitidne)</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Diagnosis of T-LGLL defined as: CD3+CD8+ cell population &gt; 650/mm^3 and the presence&#xD;
             of a clonal T-cell receptor (within 1 month of diagnosis). Note: patients with&#xD;
             myelodysplastic syndrome (MDS)-like T-LGLL may be included with principal investigator&#xD;
             (PI) approval even if CD3+CD8+ cell population is &lt; 650/mm^3, though +TCR is required.&#xD;
             Natural-killer (NK) large granular lymphocytic leukemia (LGL) is also permitted,&#xD;
             provided there is a clonal NK-cell population noted with &gt; 500 cells/mm^3&#xD;
&#xD;
          -  Failed at least one line of frontline therapy; off treatment for at least 14 days or 5&#xD;
             half-lives, whichever is longer&#xD;
&#xD;
          -  Require Treatment for T-LGLL (One or more required)&#xD;
&#xD;
               -  Symptomatic anemia with hemoglobin &lt; 10 g/dL&#xD;
&#xD;
               -  Transfusion-dependent anemia&#xD;
&#xD;
               -  Neutropenia with absolute neutrophil count (ANC) &lt; 500/mm^3&#xD;
&#xD;
               -  Neutropenia with ANC &lt; 1500/mm^3 with recurrent infections&#xD;
&#xD;
          -  Platelet count &gt;= 50 x 10^9/L&#xD;
&#xD;
          -  Serum creatinine =&lt; 2 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin &gt; 1.5&#xD;
             x ULN permitted)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Men and women of reproductive potential must agree to follow accepted birth control&#xD;
             methods for the duration of the study. Female subject is either post-menopausal or&#xD;
             surgically sterilized or willing to use an acceptable method of birth control (i.e., a&#xD;
             hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with&#xD;
             spermicide, or abstinence) for the duration of the study. Male subject agrees to use&#xD;
             an acceptable method for contraception for the duration of the study&#xD;
&#xD;
          -  Able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) less than 200/m&#xD;
&#xD;
          -  Active Infection requiring ongoing anti-microbial treatment. Patients with human&#xD;
             immunodeficiency virus (HIV), positive hepatitis B surface antigen or hepatitis C&#xD;
             antibody will be excluded&#xD;
&#xD;
          -  Concurrent immune-suppressive therapy (prednisone or equivalent up to 20 mg permitted&#xD;
             to treat T-LGL symptoms, but must be weaned within one month of initiation of trial&#xD;
             drug). Patients on stable, chronic prednisone =&lt; 10 mg for rheumatologic/autoimmune&#xD;
             conditions are exempted from this requirement. They may enroll on the study&#xD;
&#xD;
          -  Active, concurrent malignancy unless deemed related to T-LGLL by PI&#xD;
&#xD;
          -  Prior use of 5-azacytidine or decitabine&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan E Brammer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan E. Brammer, MD</last_name>
      <phone>614-293-9563</phone>
      <email>jonathan.brammer@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan E. Brammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Jonathan Brammer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

